BLSM (BlossomHill Therapeutics) Interest Income: $3.48 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $15.99
View Full Analysis

What is BlossomHill Therapeutics Interest Income?

BlossomHill Therapeutics BLSM -0.06% 8 Interest Income is $3.48 Mil as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. BlossomHill Therapeutics's interest income for the twelve months ended in Dec. 2025 was $3.48 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2025 was $3.48 Mil.

BlossomHill Therapeutics Interest Income Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Interest Income Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
Interest Income
5.71 3.48

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
Interest Income 5.71 3.48
BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Interest Income for the trailing twelve months (TTM) ended in Dec. 2025 was $3.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of $3.48 Mil mean?
BlossomHill Therapeutics (BLSM) has a Interest Income of $3.48 Mil as of Dec. 2025. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Interest Income too high?
BlossomHill Therapeutics' current Interest Income is $3.48 Mil. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Interest Income compare to ?
BlossomHill Therapeutics' Interest Income of $3.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Biotechnology company?
A good Interest Income depends on the Biotechnology industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Interest Income is $3.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Interest Income of $3.48 Mil. The current Interest Income is $3.48 Mil. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Interest Income is $3.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.99
Price